Direct Effects of Nicotine on Cranial Growth and Development

尼古丁对颅骨生长和发育的直接影响

基本信息

  • 批准号:
    9544921
  • 负责人:
  • 金额:
    $ 11.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-01 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

Here we seek to understand the direct effects of fetal and postnatal nicotine exposure on craniofacial growth and development. This area is significant as our knowledge of the concomitant effects of cigarettes have been well studied for birth defects, but little work has focused on the individual components such as nicotine. Electronic cigarettes have now entered the market without regulation and are being marketed as safe. As ~11% of pregnant women continue to smoke during pregnancy, electronic cigarettes or nicotine replacement therapies may be viewed as a safer alternative to cigarette smoking. However, our understanding of the effects of nicotine, the common component between cigarettes, electronic cigarettes, and nicotine replacement therapies, on the developing fetus, specifically the craniofacial skeleton, is poor. Smoking has been linked to an increased risk for the craniofacial birth defect, craniosynostosis. Craniosynostosis occurs in 1:1800-2500 live births and can present with a myriad of medical comorbidities including ocular proptoses, increased intracranial pressure, alter cranial volume, and mental retardation. Most diagnosed cases require neurosurgery to correct the deformity and restore normal growth trajectories. It is unknown if nicotine alone increases the risk for craniosynostosis, but nicotinic receptors have recently been identified within the growth sites of the calvaria (sutures). Here we aim to determine the effects of in utero and postnatal nicotine exposure in a dose by time of exposure manner to elucidate 1) if nicotine can alter craniofacial growth; 2) if there is a segregating effect by dose; and 3) if there is a window of susceptibility during which the fetus or infant would be most susceptible to these effects. The two areas of investigation of this project are: 1) Characterize the effect of in utero and postnatal (lactation) nicotine exposure on craniofacial growth. We will utilize our preclinical craniofacial growth model to determine the effects of nicotine in a dose by time manner. As we have previously identified nicotinic receptors within the growth sites of the skull we anticipate that increasing dose and time of exposure will result in measurable alterations in growth in our fetal and post-natal exposed animals. 2) Define the effects of nicotine on the cells of the cranial growth sites, the sutures. Nicotine is a potent stimulant drug known to have effects on cell metabolism. Here we will utilize cells garnered from the suture to determine the specific effect (proliferation, apoptosis, autophagy, osteogenesis, senescence) precipitated by nicotine exposure. In addition, we will determine the effect on nicotinic receptor expression a direct target of nicotine exposure.
在这里,我们试图了解胎儿和产后接触尼古丁对颅面部生长和发育的直接影响。 发展。这个领域很重要,因为我们对香烟的伴随影响的了解已经很深入了 对出生缺陷进行了研究,但很少有人关注尼古丁等单个成分。电子的 卷烟现已在不受监管的情况下进入市场,并被宣传为安全的。约 11% 的孕妇 女性在怀孕期间继续吸烟,电子烟或尼古丁替代疗法可能会 被视为比吸烟更安全的替代品。然而,我们对尼古丁影响的了解 香烟、电子烟和尼古丁替代疗法之间的共同成分 胎儿发育不良,特别是颅面骨骼发育不良。吸烟与以下风险增加有关 颅面出生缺陷,颅缝早闭。颅缝早闭发生在 1:1800-2500 活产婴儿中,可 存在多种医学合并症,包括眼突、颅内压增高、改变 脑容量和智力低下。大多数确诊病例需要神经外科手术来纠正畸形和 恢复正常的生长轨迹。目前尚不清楚单独使用尼古丁是否会增加颅缝早闭的风险,但 最近在颅骨(缝合线)的生长部位内发现了烟碱受体。在这里我们的目标是 确定在子宫内和产后接触尼古丁的影响(按接触时间的剂量) 阐明 1) 尼古丁是否会改变颅面生长; 2) 剂量是否存在隔离效应; 3)如果有 胎儿或婴儿最容易受到这些影响的易感窗口。 该项目的两个研究领域是: 1) 描述子宫内和产后(哺乳期)尼古丁暴露对颅面生长的影响。 我们将利用我们的临床前颅面生长模型来确定尼古丁剂量随时间的影响 方式。正如我们之前在头骨生长部位发现的烟碱受体一样,我们预计 增加剂量和暴露时间将导致胎儿和产后生长发生可测量的变化 暴露的动物。 2) 定义尼古丁对颅骨生长部位、缝线细胞的影响。 尼古丁是一种有效的兴奋剂药物,已知对细胞代谢有影响。在这里我们将利用获得的细胞 从缝合处判断具体效果(增殖、凋亡、自噬、成骨、衰老) 因接触尼古丁而诱发。此外,我们将确定对烟碱受体表达的影响 尼古丁暴露的直接目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James J. Cray其他文献

James J. Cray的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James J. Cray', 18)}}的其他基金

Direct Effects of Nicotine on Cranial Growth and Development
尼古丁对颅骨生长和发育的直接影响
  • 批准号:
    9316806
  • 财政年份:
    2017
  • 资助金额:
    $ 11.7万
  • 项目类别:
Effects of Thyroxine on the Craniosynostotic Phenotype
甲状腺素对颅缝早闭表型的影响
  • 批准号:
    8636699
  • 财政年份:
    2013
  • 资助金额:
    $ 11.7万
  • 项目类别:
Effects of Thyroxine on the Craniosynostotic Phenotype
甲状腺素对颅缝早闭表型的影响
  • 批准号:
    8920690
  • 财政年份:
    2013
  • 资助金额:
    $ 11.7万
  • 项目类别:
T-COHR: Summer Undergraduate Research Program
T-COHR:暑期本科生研究计划
  • 批准号:
    9068068
  • 财政年份:
    2012
  • 资助金额:
    $ 11.7万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 11.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 11.7万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 11.7万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 11.7万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 11.7万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 11.7万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 11.7万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 11.7万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 11.7万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 11.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了